<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-43006" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Tyramine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burns</surname>
            <given-names>Corey</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kidron</surname>
            <given-names>Ariel</given-names>
          </name>
          <aff>Nova Southeastern College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Corey Burns declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ariel Kidron declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-43006.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tyramine is a trace monoamine with sympathomimetic properties. It is naturally found in foods, plants, and animals. By definition, all monoamines have an amine group separated from an aromatic ring by a 2-carbon chain. Dopamine, norepinephrine, and serotonin are monoamines. Trace monoamines were named for their relatively low frequency in mammalian tissues compared to their more abundant and discussed monoamine neurotransmitter counterparts: epinephrine, norepinephrine, dopamine, and serotonin.<xref ref-type="bibr" rid="article-43006.r1">[1]</xref></p>
        <p>Other trace amines include octopamine, phenethylamine, N-methylphenethylamine, and N-methyltyramine. Tyramine is degraded by several enzymes, most notably monoamine oxidase. Tyramine is often found in fermented, aged, cured, and spoiled foods where microbes with decarboxylase enzymes convert the amino acid tyrosine into tyramine.<xref ref-type="bibr" rid="article-43006.r2">[2]</xref> Ingestion of high tyrosine-containing foods in patients taking monoamine oxidase inhibitors produces headaches, blurry vision, chest pain, and palpitations associated with hypertension, intracranial hemorrhages, and myocardial injury.<xref ref-type="bibr" rid="article-43006.r3">[3]</xref>&#x000a0;Tyramine has long been shown to cause cardiovascular effects when consumed in large, pathologic amounts.<xref ref-type="bibr" rid="article-43006.r4">[4]</xref> &#x000a0;New evidence suggests endogenous tyramine and other trace amines in lower physiologic levels may have additional roles, including modulating the immune system.<xref ref-type="bibr" rid="article-43006.r5">[5]</xref></p>
      </sec>
      <sec id="article-43006.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>Tyramine is a trace monoamine with indirect catecholamine-releasing properties.<xref ref-type="bibr" rid="article-43006.r1">[1]</xref>&#x000a0;Ingested tyramine produces mostly peripheral cardiovascular effects. Ingestion of large amounts of tyramine, especially combined with monoamine oxidase inhibitors (MAOIs), can precipitate a hypertensive crisis.<xref ref-type="bibr" rid="article-43006.r2">[2]</xref> A hypertensive crisis&#x000a0;escalates from hypertensive urgency to a hypertensive emergency once there is evidence of end-organ damage such as retinal hemorrhages, papilledema, intracranial bleeds, pulmonary edema, or acute renal failure.<xref ref-type="bibr" rid="article-43006.r6">[6]</xref> An adrenergic crisis induced by taking MAOI and consuming a high amount of tyramine can have a rapid onset, occurring in minutes.</p>
      </sec>
      <sec id="article-43006.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Hypertensive crisis after tyramine ingestion also referred to as the &#x0201c;cheese effect,&#x0201d; has become increasingly rare. Most documented cases occur in individuals receiving monoamine oxidase inhibitors, which have largely been replaced by newer classes of antidepressants with more selectivity and fewer side effects.<xref ref-type="bibr" rid="article-43006.r7">[7]</xref>&#x000a0;Monoamine oxidase inhibitors are also used to treat Parkinson disease to slow the breakdown of levodopa and dopamine.<xref ref-type="bibr" rid="article-43006.r8">[8]</xref>&#x000a0;Food production and storage improvements have led to a decrease in tyramine-containing foods.<xref ref-type="bibr" rid="article-43006.r9">[9]</xref></p>
        <p>Tyramine and other biogenic amines (eg, histamine) formed from the decarboxylation of amino acids have been minimized in food production by the advent of culture starters with reduced carboxylase-producing organisms.<xref ref-type="bibr" rid="article-43006.r10">[10]</xref><xref ref-type="bibr" rid="article-43006.r11">[11]</xref>&#x000a0;Modern improvements in food storage (eg, temperature, pH, and packaging) decrease tyrosine decarboxylase activity, further reducing tyramine levels in modern foods. Biogenic amines are a marker for food safety.<xref ref-type="bibr" rid="article-43006.r12">[12]</xref> Nonetheless, physicians should counsel patients taking monoamine oxidase inhibitors to avoid fermented or cured foods high in tyramine. This includes</p>
        <list list-type="bullet">
          <list-item>
            <p>Fermented vegetables, including kimchi and sauerkraut,</p>
          </list-item>
          <list-item>
            <p>Select fresh produce, including grapes, avocado, and beetroot</p>
          </list-item>
          <list-item>
            <p>Wine and beer,</p>
          </list-item>
          <list-item>
            <p>Cheese, especially cheddar and feta</p>
          </list-item>
          <list-item>
            <p>Cured or salt-dried meats</p>
          </list-item>
          <list-item>
            <p>Chocolate</p>
          </list-item>
          <list-item>
            <p>Coffee</p>
          </list-item>
          <list-item>
            <p>Soy sauce, Worcestershire sauce</p>
          </list-item>
          <list-item>
            <p>Pickled or salt-dried fish or shrimp<xref ref-type="bibr" rid="article-43006.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Ingestion of 10&#x000a0;to 25mg of tyramine in patients taking MAOIs produces a severe adrenergic response, including hypertension, headaches, and possible intracranial hemorrhage.<xref ref-type="bibr" rid="article-43006.r14">[14]</xref>&#x000a0;Although not completely understood, tyramine-containing foods are known triggers for patients with migraines.<xref ref-type="bibr" rid="article-43006.r15">[15]</xref> The adrenergic effects of tyramine may be responsible for the migraine phenomena.<xref ref-type="bibr" rid="article-43006.r16">[16]</xref>&#x000a0;Diets low in tyramine can be recommended when aiming to identify migraine triggers.&#x000a0;</p>
      </sec>
      <sec id="article-43006.s4" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>Tyramine exerts its vasopressor response as it is an indirectly acting sympathomimetic agent. Taken up by the NET- Norepinephrine reuptake transporter and precipitates the release of large quantities of norepinephrine into circulation<xref ref-type="bibr" rid="article-43006.r17">[17]</xref>. Tyramine acts on the adipose tissues and has a dose-dependent antilipolytic effect. The antilipolytic effect is due to the inhibition of protein tyrosine phosphatases, which is absent in the presence of ascorbic acid, a natural antioxidant.<xref ref-type="bibr" rid="article-43006.r18">[18]</xref></p>
      </sec>
      <sec id="article-43006.s5" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>The administration of tyramine displaces norepinephrine, epinephrine, and dopamine from pre-synaptic storage vesicles.<xref ref-type="bibr" rid="article-43006.r19">[19]</xref> The release of these neurotransmitters, particularly norepinephrine, is responsible for vasoconstriction, increased heart rate, and a rise in blood pressure. Therefore, tyramine functions as an indirect sympathomimetic by causing the release of presynaptic endogenous neurotransmitters. Tyramine acts as a substrate for monoamine oxidase, further limiting the breakdown of monoamine neurotransmitters.<xref ref-type="bibr" rid="article-43006.r20">[20]</xref></p>
        <p>When not ingested, tyramine is made endogenously from the decarboxylation of the amino acid tyrosine by the enzyme aromatic L-amino acid decarboxylase.<xref ref-type="bibr" rid="article-43006.r1">[1]</xref> This is the same enzyme that converts L-DOPA to dopamine. Monoamine oxidase converts tyramine to the inactive metabolite hydroxyphenyl acetic acid.<xref ref-type="bibr" rid="article-43006.r21">[21]</xref> Tyramine can be converted to active secondary amines octopamine by the enzyme dopamine b-hydroxylase or N-methyltyramine by phenylethanolamine N-methyltransferase. Octopamine can then be converted to synephrine by phenylethanolamine N-methyltransferase as well.<xref ref-type="bibr" rid="article-43006.r21">[21]</xref></p>
      </sec>
      <sec id="article-43006.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>New evidence has also revealed G-protein coupled receptors that tyramine and other biogenic amines bind to directly, called Trace amine-associated receptors (TAARs).<xref ref-type="bibr" rid="article-43006.r1">[1]</xref> Tyramine has a high affinity for binding TAAR1 and TAAR2. These receptors are found in the central nervous system and periphery. These receptors are the focus of recent research on endogenous trace amines. &#x000a0;The function of this class of receptors is still being elucidated and is hypothesized to include olfaction, modulation of other neurotransmitters, regulation of body weight, and immunologic functions.<xref ref-type="bibr" rid="article-43006.r1">[1]</xref><xref ref-type="bibr" rid="article-43006.r22">[22]</xref>&#x000a0;TAAR1 signal transduction may modulate the reward circuits, the limbic system, and mood in the central nervous system.<xref ref-type="bibr" rid="article-43006.r23">[23]</xref></p>
        <p>TAAR1 has been found in large amounts in the stomach and small intestine and may play a role in the brain-gut-microbiome axis.<xref ref-type="bibr" rid="article-43006.r24">[24]</xref>&#x000a0;TAAR1 is the only subtype not represented in the olfactory epithelium; however, the utility of TAAR subtypes in olfaction is still being studied.<xref ref-type="bibr" rid="article-43006.r24">[24]</xref>&#x000a0;One study found an association between single-nucleotide polymorphism (SNPs) in the TAAR1 gene and fibromyalgia.<xref ref-type="bibr" rid="article-43006.r25">[25]</xref>&#x000a0;The peripheral vascular effects and resulting hypertension with tyramine ingestion, long attributed to norepinephrine displacement, may partly be the result of TAAR1 binding mechanisms as well.<xref ref-type="bibr" rid="article-43006.r26">[26]</xref></p>
      </sec>
      <sec id="article-43006.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Counseling patients to avoid tyramine-containing foods when taking MAOIs remains the standard of care. Patients on MAOI should be instructed to record their blood pressure. Maintaining a high index of suspicion and inquiring about tyramine consumption-containing foods in hypertensive patients on MAOIs can aid in diagnosis. The physiologic effects of irreversible MAOIs such as tranylcypromine, phenelzine, and selegiline can persist for up to 3 weeks, and tyramine avoidance should continue. Dietary counseling for patients taking MAOIs should begin before therapy, continue during follow-up to monitor compliance, and include</p>
        <list list-type="bullet">
          <list-item>
            <p>Education on a low tyramine diet with consumption of only fresh foods</p>
          </list-item>
          <list-item>
            <p>Identification and avoidance&#x000a0;of high tyramine foods</p>
          </list-item>
          <list-item>
            <p>Instructions to begin the diet before MAOI therapy and continue for&#x000a0;4 weeks after stopping MAOIs<xref ref-type="bibr" rid="article-43006.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>Tyramine has been implicated as a potential migraine trigger.<xref ref-type="bibr" rid="article-43006.r16">[16]</xref> The role of trace amine-associated receptors and their biogenic amine ligands in physiologic concentrations, such as tyramine, requires additional study.</p>
      </sec>
      <sec id="article-43006.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43006&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43006">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/43006/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=43006">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-43006.s9">
        <title>References</title>
        <ref id="article-43006.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gainetdinov</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hoener</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Trace Amines and Their Receptors.</article-title>
            <source>Pharmacol Rev</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>549</fpage>
            <page-range>549-620</page-range>
            <pub-id pub-id-type="pmid">29941461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>1707</fpage>
            <page-range>1707-1717</page-range>
            <pub-id pub-id-type="pmid">30255284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kenney</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myocardial Injury from Tranylcypromine-Induced Hypertensive Crisis Secondary to Excessive Tyramine Intake.</article-title>
            <source>Cardiovasc Toxicol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-586</page-range>
            <pub-id pub-id-type="pmid">30083815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators.</article-title>
            <source>J Neurochem</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-71</page-range>
            <pub-id pub-id-type="pmid">15228583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Terrazzino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fortin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farruggio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes.</article-title>
            <source>Neurosci Lett</source>
            <year>2003</year>
            <month>Jul</month>
            <day>31</day>
            <volume>346</volume>
            <issue>1-2</issue>
            <fpage>89</fpage>
            <page-range>89-92</page-range>
            <pub-id pub-id-type="pmid">12850555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varounis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katsi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lekakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tousoulis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Hypertensive Crisis: Recent Evidence and Review of the Literature.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2016</year>
            <volume>3</volume>
            <fpage>51</fpage>
            <pub-id pub-id-type="pmid">28119918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnan</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Revisiting monoamine oxidase inhibitors.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2007</year>
            <volume>68 Suppl 8</volume>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">17640156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasuhara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of MAO inhibitors: safety and future.</article-title>
            <source>Neurotoxicology</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1-2</issue>
            <fpage>215</fpage>
            <page-range>215-21</page-range>
            <pub-id pub-id-type="pmid">14697896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doeun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davaatseren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Biogenic amines in foods.</article-title>
            <source>Food Sci Biotechnol</source>
            <year>2017</year>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1463</fpage>
            <page-range>1463-1474</page-range>
            <pub-id pub-id-type="pmid">30263683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laranjo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Potes</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Role of Starter Cultures on the Safety of Fermented Meat Products.</article-title>
            <source>Front Microbiol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>853</fpage>
            <pub-id pub-id-type="pmid">31133993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tangwatcharin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nithisantawakhup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sorapukdee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Selection of indigenous starter culture for safety and its effect on reduction of biogenic amine content in Moo som.</article-title>
            <source>Asian-Australas J Anim Sci</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>1580</fpage>
            <page-range>1580-1590</page-range>
            <pub-id pub-id-type="pmid">30744331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz-Capillas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herrero</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Impact of Biogenic Amines on Food Quality and Safety.</article-title>
            <source>Foods</source>
            <year>2019</year>
            <month>Feb</month>
            <day>08</day>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30744001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marcinek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sulzinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schieberle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krautwurst</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Food sources and biomolecular targets of tyramine.</article-title>
            <source>Nutr Rev</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-115</page-range>
            <pub-id pub-id-type="pmid">30165672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCabe</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Dietary tyramine and other pressor amines in MAOI regimens: a review.</article-title>
            <source>J Am Diet Assoc</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>1059</fpage>
            <page-range>1059-64</page-range>
            <pub-id pub-id-type="pmid">3525654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nordera</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Allais</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Granella</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism.</article-title>
            <source>Neurol Sci</source>
            <year>2007</year>
            <month>May</month>
            <volume>28 Suppl 2</volume>
            <fpage>S94</fpage>
            <page-range>S94-6</page-range>
            <pub-id pub-id-type="pmid">17508188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghose</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coppen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carrol</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Intravenous tyramine response in migraine before and during treatment with indoramin.</article-title>
            <source>Br Med J</source>
            <year>1977</year>
            <month>May</month>
            <day>07</day>
            <volume>1</volume>
            <issue>6070</issue>
            <fpage>1191</fpage>
            <page-range>1191-3</page-range>
            <pub-id pub-id-type="pmid">324566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trupin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A perspective on the editorial by Ken Gillman: '"Much ado about nothing': monoamine oxidase inhibitors, drug interactions, and dietary tyramine''.</article-title>
            <source>CNS Spectr</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>390</fpage>
            <pub-id pub-id-type="pmid">28625201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carp&#x000e9;n&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Galitzky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zakaroff-Girard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of the antilipolytic response of human adipocytes to tyramine, a trace amine present in food.</article-title>
            <source>J Physiol Biochem</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>623</fpage>
            <page-range>623-633</page-range>
            <pub-id pub-id-type="pmid">30039351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raiteri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Carmine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertollini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1977</year>
            <month>Jan</month>
            <day>21</day>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-43</page-range>
            <pub-id pub-id-type="pmid">832672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The monoamine oxidase inhibitor-tyramine interaction.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1989</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">2666453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindemann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoener</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>A renaissance in trace amines inspired by a novel GPCR family.</article-title>
            <source>Trends Pharmacol Sci</source>
            <year>2005</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>274</fpage>
            <page-range>274-81</page-range>
            <pub-id pub-id-type="pmid">15860375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babusyte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotthoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiedler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krautwurst</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Biogenic amines activate blood leukocytes via trace amine-associated receptors TAAR1 and TAAR2.</article-title>
            <source>J Leukoc Biol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-94</page-range>
            <pub-id pub-id-type="pmid">23315425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gainetdinov</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hoener</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Shahid</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges.</article-title>
            <source>Pharmacol Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>180</volume>
            <fpage>161</fpage>
            <page-range>161-180</page-range>
            <pub-id pub-id-type="pmid">28723415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bugda Gwilt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Olliffe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoffing</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Puzan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Aidy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1).</article-title>
            <source>Cell Mol Neurobiol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-201</page-range>
            <pub-id pub-id-type="pmid">31836967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Maixner</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fillingim</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Slade</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gracely</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ambrose</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zaykin</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Hyde</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maixner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Diatchenko</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>584</fpage>
            <page-range>584-93</page-range>
            <pub-id pub-id-type="pmid">21905019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43006.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broadley</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>The vascular effects of trace amines and amphetamines.</article-title>
            <source>Pharmacol Ther</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>363</fpage>
            <page-range>363-75</page-range>
            <pub-id pub-id-type="pmid">19948186</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
